Reviewing AngioSoma (OTCMKTS:SOAN) and NovaBay Pharmaceuticals (NYSEAMERICAN:NBY)

AngioSoma (OTCMKTS:SOAN) and NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, earnings, risk and institutional ownership.

Volatility & Risk

AngioSoma has a beta of -0.46, meaning that its share price is 146% less volatile than the S&P 500. Comparatively, NovaBay Pharmaceuticals has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500.

Profitability

This table compares AngioSoma and NovaBay Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AngioSoma	N/A	N/A	-1,245.34%
NovaBay Pharmaceuticals	N/A	-297.77%	-140.10%

Earnings & Valuation

This table compares AngioSoma and NovaBay Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AngioSoma	N/A	N/A	-$540,000.00	N/A	N/A
NovaBay Pharmaceuticals	$9.78 million	0.77	-$7.22 million	($9.95)	-0.13

AngioSoma has higher earnings, but lower revenue than NovaBay Pharmaceuticals.

Insider and Institutional Ownership

0.0% of AngioSoma shares are held by institutional investors. Comparatively, 23.3% of NovaBay Pharmaceuticals shares are held by institutional investors. 20.1% of NovaBay Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and target prices for AngioSoma and NovaBay Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AngioSoma	0	0	0	0	0.00
NovaBay Pharmaceuticals	0	0	1	0	3.00

NovaBay Pharmaceuticals has a consensus target price of $0.85, suggesting a potential downside of 32.54%. Given AngioSoma’s higher probable upside, equities analysts plainly believe AngioSoma is more favorable than NovaBay Pharmaceuticals.

Summary

NovaBay Pharmaceuticals beats AngioSoma on 7 of the 10 factors compared between the two stocks.

About AngioSoma

AngioSoma, Inc., a wellness company, engages in the development and commercialization of dietary supplements to the medical, wellness, and adult-use markets. The company was founded in 2016 and is based in Houston, Texas.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc. develops and sells eyecare and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; Avenova Eye Health Support antioxidant-rich oral supplements; Avenova Lubricating Eye Drops for instant relief; NovaWipes by Avenova; Avenova WarmEye Compress to soothe the eyes; and the i-Chek by Avenova to monitor physical eyelid health. The company also provides wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. It sells its products through the company's web stores, third-party online retailers and distribution partners. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.